Sanuwave withdraws FY2026 revenue guidance amid CMS proposal implying 97610 reimbursement of $316.59 in 2027 (NASDAQ:SNWV)
· seekingalpha.com
SANUWAVE (SNWV) Q2 2026 earnings call: record UltraMIST applicator sales, weak system demand, CMS reimbursement risks, and guidance withdrawal—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...